What are the effects of nirmatrelvir combined with ritonavir for treating COVID‐19 in the outpatient setting? – Tort, Sera – 2022 | Cochrane Library
Cochrane Clinical Answers Clinical Answer: For unvaccinated, non‐hospitalized people with symptomatic COVID‐19 at high risk of progression to severe COVID‐19, low‐certainty evidence suggests that fewer people may die and experience worsened clinical status at day 28 with nirmatrelvir/ritonavir compared with placebo (11 and 53 fewer people per 1000, respectively; all results on average)….
